Pharvaris N.V. (PHVS) shareholders
PHVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$33.83−0.35 (-1.02%)
Close on Nov 12, 2026Market cap $2.21BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
99.2%
65M of 65M shares
Institutional holders
125
24 new, 9 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
0 buys · 71 sales
Net sold $33.02M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| General Atlantic Cooperatief U.A. Joint filing with General Atlantic, L.P. (7.60%), General Atlantic PH B.V. (7.60%) and 12 more | 5,359,727 | 7.60% | 13G (passive) amendment | Jun 30, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (9.99%) | 5,192,984 | 9.99% | 13G (passive) amendment | Feb 9, 2024 |
| Corey Goodman Joint filing with Robert Adelman (8.40%), venBio Global Strategic Fund III, L.P. (6.80%) and 2 more | 4,382,504 | 8.40% | 13D (active) amendment | Jan 24, 2024 |
| Foresite Capital Management IV, LLC (“FCM IV”) Joint filing with Foresite Capital Fund IV, L.P. (“FCF IV”) (7.80%), James Tananbaum (“Tananbaum”) (7.80%) | 4,038,842 | 7.80% | 13G (passive) amendment | Dec 31, 2023 |
| Shabet Rose Sharon Joint filing with Viking Global Investors LP (5.60%), Viking Global Opportunities Parent GP LLC (5.60%) and 4 more | 3,653,310 | 5.60% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PHVS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 6,565,272 | 10.07% | $227.03M | +280,800 | 0.01% |
| General Atlantic, L.P. | 6,550,757 | 10.05% | $226.53M | −1,480,495 | 7.79% |
| Foresite Capital Management IV, LLC | 4,778,581 | 7.33% | $165.24M | – | 56.95% |
| venBio Partners LLC | 4,643,430 | 7.12% | $160.57M | +4,126 | 30.92% |
| Viking Global Investors LP | 3,653,310 | 5.60% | $126.33M | – | 0.36% |
| EQT Fund Management S.a r.l. | 3,424,609 | 5.25% | $118.42M | – | 13.73% |
| Deerfield Management Company, L.P. (Series C) | 3,376,042 | 5.18% | $116.74M | +250,000 | 1.22% |
| Bain Capital Life Sciences Investors, LLC | 2,675,509 | 4.10% | $92.52M | – | 5.50% |
| Wellington Management Group Llp | 2,392,934 | 3.67% | $82.75M | +274,034 | 0.01% |
| Polar Capital Holdings Plc | 2,326,389 | 3.57% | $80.45M | +1,545,373 | 0.19% |
| Point72 Asset Management, L.P. | 1,641,200 | 2.52% | $56.75M | +634,184 | 0.06% |
| Commodore Capital LP | 1,425,000 | 2.19% | $49.28M | −493,970 | 2.93% |
| Novo Holdings A/S | 1,400,000 | 2.15% | $48.41M | −350,000 | 2.81% |
| Saturn V Capital Management LP | 1,314,122 | 2.02% | $45.44M | +112,720 | 6.52% |
| TCG Crossover Management, LLC | 1,008,229 | 1.55% | $34.86M | New | 0.84% |
| Sofinnova Investments, Inc. | 881,299 | 1.35% | $30.48M | +62,971 | 1.58% |
| 5AM Venture Management, LLC | 797,600 | 1.22% | $27.58M | – | 9.58% |
| Seven Fleet Capital Management LP | 774,501 | 1.19% | $26.78M | +601,770 | 4.42% |
| BlackRock, Inc. | 771,454 | 1.18% | $26.68M | +14,241 | 0.00% |
| Cormorant Asset Management, LP | 750,000 | 1.15% | $25.94M | −250,000 | 1.33% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 125 | 65M | 99.2% | 24 / 49 | 33 / 9 | 10M | 4M |
| Q1 2026 | 110 | 59M | 90.8% | 11 / 35 | 35 / 6 | 3M | 2M |
| Q4 2025 | 106 | 59M | 90.5% | 31 / 42 | 15 / 6 | 6M | 5M |
| Q3 2025 | 83 | 58M | 88.7% | 29 / 38 | 9 / 6 | 15M | 2M |
| Q2 2025 | 60 | 45M | 69.1% | 9 / 19 | 16 / 1 | 2M | 1M |
| Q1 2025 | 52 | 45M | 68.9% | 3 / 15 | 14 / 5 | 1M | 0M |
| Q4 2024 | 54 | 45M | 68.5% | 9 / 19 | 12 / 6 | 1M | 1M |
| Q3 2024 | 51 | 45M | 69.1% | 19 / 13 | 6 / 3 | 2M | 0M |
| Q2 2024 | 36 | 43M | 66.0% | 5 / 10 | 9 / 4 | 1M | 1M |
| Q1 2024 | 35 | 42M | 65.2% | 6 / 12 | 9 / 7 | 4M | 2M |
| Q4 2023 | 36 | 41M | 62.5% | 18 / 12 | 4 / 3 | 13M | 1M |
| Q3 2023 | 21 | 29M | 44.6% | 3 / 6 | 6 / 3 | 1M | 1M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Berndt Modig | Chief Executive Officer, Director | 778,334 | 1.19% | Sep 21, 2026 |
| Peng Lu | President | 110,035 | 0.17% | Oct 13, 2026 |
| David W. Nassif | CFO / CLO | 114,300 | 0.18% | Sep 23, 2026 |
| Anne Lesage | Chief Early Development | 130,419 | 0.20% | Sep 21, 2026 |
| Stefan Andreas Abele | Chief Technical Ops Officer | 40,468 | 0.06% | Sep 17, 2026 |
| Wim Souverijns | Chief Commercial Officer | 39,021 | 0.06% | Sep 16, 2026 |
| Anna Nijdam | Principal Accounting Officer | 46,275 | 0.07% | Jun 8, 2026 |
| Annick Deschoolmeester | Chief Human Resources Officer | 92,553 | 0.14% | Mar 18, 2026 |
| Viviane Monges | Director | 17,469 | 0.03% | Sep 25, 2026 |
| Johannes Gerardus Christiaan Petrus Schikan | Director | 115,167 | 0.18% | Sep 24, 2026 |
| Robert Glassman | Director | 10,500 | 0.02% | Sep 21, 2026 |
| Elisabeth Bjork | Director | 15,167 | 0.02% | Sep 21, 2026 |
| David P. Meeker | Director | 65,167 | 0.10% | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Peng Lu President | Oct 12, 2026 | Tax withholding | −117 | $31.10 | $3.64K | 110,035 |
| Peng Lu President | Oct 11, 2026 | Tax withholding | −109 | $31.10 | $3.39K | 110,152 |
| Viviane Monges Director | Sep 23, 2026 | Option exercise | +11,969 | $8.05 | $96.35K | 17,469 |
| Viviane Monges Director | Sep 23, 2026 | Sale | −11,969 | $33.05 | $395.58K | 5,500 |
| Peng Lu President | Sep 22, 2026 | Option exercise | +45,308 | $2.59 | $117.35K | 110,261 |
| Johannes Gerardus Christiaan Petrus Schikan Director | Sep 22, 2026 | Sale | −800 | $36.19 | $28.95K | 115,167 |
| Johannes Gerardus Christiaan Petrus Schikan Director | Sep 22, 2026 | Option exercise | +800 | $20.00 | $16.00K | 115,967 |
| David W. Nassif CFO / CLO | Sep 21, 2026 | Sale | −6,000 | $36.47 | $218.82K | 114,300 |
| David W. Nassif CFO / CLO | Sep 21, 2026 | Gift | −500 | – | – | 113,800 |
| Anne Lesage Chief Early Development | Sep 17, 2026 | Sale | −20,000 | $38.27 | $765.40K | 73,969 |
| Robert Glassman Director | Sep 17, 2026 | Sale(10b5-1 plan) | −14,493 | $38.56 | $558.85K | 10,500 |
| Robert Glassman Director | Sep 17, 2026 | Option exercise | +14,493 | $18.14 | $262.90K | 24,993 |
| Peng Lu President | Sep 17, 2026 | Sale | −100,000 | $35.00 | $3.50M | 64,953 |
| Peng Lu President | Sep 17, 2026 | Option exercise | +100,000 | $2.59 | $259.00K | 164,953 |
| Johannes Gerardus Christiaan Petrus Schikan Director | Sep 17, 2026 | Sale | −200,000 | $35.00 | $7.00M | 115,167 |
| Elisabeth Bjork Director | Sep 17, 2026 | Sale | −52,500 | $37.89 | $1.99M | 15,167 |
| Elisabeth Bjork Director | Sep 17, 2026 | Option exercise | +17,500 | $18.14 | $317.45K | 67,667 |
| Elisabeth Bjork Director | Sep 17, 2026 | Option exercise | +35,000 | $14.39 | $503.65K | 50,167 |
| Berndt Modig Chief Executive Officer, Director | Sep 17, 2026 | Option exercise | −300,000 | $35.00 | $10.50M | 650,000 |
| Robert Glassman Director | Sep 15, 2026 | Sale(10b5-1 plan) | −8,667 | $38.27 | $331.69K | 10,500 |
| Robert Glassman Director | Sep 15, 2026 | Option exercise | +8,667 | $22.31 | $193.36K | 19,167 |
| Stefan Andreas Abele Chief Technical Ops Officer | Sep 15, 2026 | Sale | −45,000 | $38.14 | $1.72M | 40,468 |
| Stefan Andreas Abele Chief Technical Ops Officer | Sep 15, 2026 | Option exercise | +45,000 | $16.40 | $738.00K | 85,468 |
| Stefan Andreas Abele Chief Technical Ops Officer | Sep 15, 2026 | Sale | −1,400 | $39.24 | $54.94K | 39,068 |
| Wim Souverijns Chief Commercial Officer | Sep 15, 2026 | Sale(10b5-1 plan) | −6,090 | $38.99 | $237.45K | 39,021 |
| Wim Souverijns Chief Commercial Officer | Sep 14, 2026 | Option exercise | +20,000 | $17.43 | $348.60K | 65,111 |
| Wim Souverijns Chief Commercial Officer | Sep 14, 2026 | Sale(10b5-1 plan) | −20,000 | $39.31 | $786.20K | 45,111 |
| Berndt Modig Chief Executive Officer, Director | Sep 14, 2026 | Sale(10b5-1 plan) | −2,291 | $39.40 | $90.27K | 128,334 |
| Peng Lu President | Sep 14, 2026 | Tax withholding | −117 | $38.02 | $4.45K | 64,953 |
| Peng Lu President | Sep 11, 2026 | Option exercise | +15,000 | $2.59 | $38.85K | 80,179 |
| Peng Lu President | Sep 11, 2026 | Sale(10b5-1 plan) | −15,000 | $40.13 | $601.95K | 65,179 |
| Peng Lu President | Sep 11, 2026 | Tax withholding | −109 | $37.51 | $4.09K | 65,070 |
| Anne Lesage Chief Early Development | Sep 10, 2026 | Sale(10b5-1 plan) | −30,000 | $38.30 | $1.15M | 56,450 |
| Anne Lesage Chief Early Development | Sep 10, 2026 | Option exercise | +30,000 | $8.05 | $241.50K | 86,450 |
| Robert Glassman Director | Sep 9, 2026 | Option exercise | +8,000 | $20.00 | $160.00K | 18,500 |
| Robert Glassman Director | Sep 9, 2026 | Sale(10b5-1 plan) | −8,000 | $37.55 | $300.40K | 10,500 |
| Peng Lu President | Sep 8, 2026 | Sale(10b5-1 plan) | −15,000 | $40.68 | $610.20K | 65,179 |
| Peng Lu President | Sep 8, 2026 | Option exercise | +15,000 | $2.59 | $38.85K | 80,179 |
| Berndt Modig Chief Executive Officer, Director | Aug 14, 2026 | Sale(10b5-1 plan) | −2,292 | $34.77 | $79.69K | 130,625 |
| Peng Lu President | Aug 12, 2026 | Tax withholding | −117 | $34.42 | $4.03K | 65,179 |
| Peng Lu President | Aug 11, 2026 | Tax withholding | −109 | $34.84 | $3.80K | 65,296 |
| Berndt Modig Chief Executive Officer, Director | Jul 13, 2026 | Sale(10b5-1 plan) | −2,292 | $34.97 | $80.15K | 132,917 |
| Peng Lu Chief Medical Officer | Jul 12, 2026 | Tax withholding | −117 | $35.07 | $4.10K | 65,405 |
| Peng Lu Chief Medical Officer | Jul 11, 2026 | Tax withholding | −109 | $35.07 | $3.82K | 65,522 |
| Johannes Gerardus Christiaan Petrus Schikan Director | Jun 30, 2026 | Sale(10b5-1 plan) | −30,712 | $35.49 | $1.09M | 315,167 |
| Anne Lesage Chief Early Development | Jun 30, 2026 | Sale(10b5-1 plan) | −30,703 | $35.49 | $1.09M | 93,969 |
| Anne Lesage Chief Early Development | Jun 30, 2026 | Sale(10b5-1 plan) | −27,872 | $35.48 | $988.90K | 58,750 |
| Anne Lesage Chief Early Development | Jun 30, 2026 | Option exercise | +24,900 | $8.05 | $200.45K | 86,622 |
| Anne Lesage Chief Early Development | Jun 30, 2026 | Option exercise | +2,972 | $2.59 | $7.70K | 61,722 |
| Johannes Gerardus Christiaan Petrus Schikan Director | Jun 29, 2026 | Sale(10b5-1 plan) | −6,888 | $35.05 | $241.42K | 345,879 |
| Anne Lesage Chief Early Development | Jun 29, 2026 | Sale(10b5-1 plan) | −6,997 | $35.05 | $245.24K | 124,672 |
| Anne Lesage Chief Early Development | Jun 29, 2026 | Sale(10b5-1 plan) | −8,300 | $35.05 | $290.92K | 58,750 |
| Anne Lesage Chief Early Development | Jun 29, 2026 | Sale(10b5-1 plan) | −2,300 | $35.12 | $80.78K | 56,450 |
| Anne Lesage Chief Early Development | Jun 29, 2026 | Option exercise | +4,200 | $8.05 | $33.81K | 67,050 |
| Anne Lesage Chief Early Development | Jun 29, 2026 | Option exercise | +4,100 | $2.59 | $10.62K | 56,450 |
| Anne Lesage Chief Early Development | Jun 29, 2026 | Option exercise | +900 | $8.05 | $7.25K | 58,750 |
| Anne Lesage Chief Early Development | Jun 29, 2026 | Option exercise | +1,400 | $2.59 | $3.63K | 57,850 |
| Johannes Gerardus Christiaan Petrus Schikan Director | Jun 29, 2026 | Sale(10b5-1 plan) | −2,400 | $35.10 | $84.24K | 352,767 |
| Peng Lu Chief Medical Officer | Jun 26, 2026 | Option exercise | +14,700 | $2.59 | $38.07K | 80,331 |
| Peng Lu Chief Medical Officer | Jun 26, 2026 | Sale(10b5-1 plan) | −14,700 | $34.00 | $499.80K | 65,631 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
3M shares short
Days to cover
3.6
At 1M shares a day
Change since last report
+3.0%
From 2M shares
Short volume, 20 days
38.2%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Pharvaris's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,009 shares on Oct 1, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Viviane Rosine Francoise Beck Monges Director | Sep 23, 2026 | 11,969 | $395.52K | Sep 23, 2026 | Exercise of Options Under a Registered Plan |
| Johannes Ger. Chris. Pe Schikan Officer, Director | Sep 22, 2026 | 200,000 | $7.00M | Sep 17, 2026 | Founder Stock |
| Johannes Ger. Chris. Pe Schikan Director | Sep 22, 2026 | 800 | $28.95K | Sep 22, 2026 | Exercise of Options Under a Registered Plan |
| David W. Nassif Officer | Sep 21, 2026 | 6,000 | $218.80K | Sep 21, 2026 | Restricted Stock |
| Peng Lu Officer | Sep 17, 2026 | 100,000 | $3.50M | Sep 17, 2026 | Exercise of Options Under a Registered Plan |
| Johannes Ger. Chris. Pe Schikan Officer, Director | Sep 17, 2026 | 200,000 | $7.00M | Sep 17, 2026 | Founder Stock |
| Schoodic Management Bv Officer, Director | Sep 17, 2026 | 300,000 | $10.50M | Sep 17, 2026 | Founder Stock |
| Elisabeth Bjork Director | Sep 17, 2026 | 52,500 | $1.99M | Sep 17, 2026 | Stock Option Exercise |
| Graymatters Consulting Officer | Sep 17, 2026 | 20,000 | $765.47K | Sep 17, 2026 | Founder Stock |
| Robert Glassman Director | Sep 17, 2026 | 14,493 | $558.81K | Sep 17, 2026 | Stock Option Exercise |
| Stefan Andreas Abele Officer | Sep 15, 2026 | 46,400 | $1.77M | Sep 15, 2026 | Stock Option Exercise |
| Robert Glassman Director | Sep 15, 2026 | 8,667 | $331.72K | Sep 15, 2026 | Stock Option Exercise |
| Berndt Modig Director, Officer | Sep 14, 2026 | 2,291 | $87.10K | Sep 14, 2026 | Restricted Stock Units |
| Wim Souverijns Officer | Sep 14, 2026 | 26,090 | $1.02M | Sep 14, 2026 | Restricted Stock |
| Anne Lesage Officer | Sep 10, 2026 | 30,000 | $1.15M | Sep 10, 2026 | Stock Option Exercise |
See a number that looks wrong?